PL2250161T3 - Związki mające aktywność antagonisty CRTH2 - Google Patents

Związki mające aktywność antagonisty CRTH2

Info

Publication number: PL2250161T3
Authority: PL; Poland
Prior art keywords: compounds; antagonist activity; crth2 antagonist; crth2; activity
Prior art date: 2008-01-18

Application number

PL09702598T

Other languages

English (en)

Inventor

Richard Edward Armer

Eric Roy Pettipher

Mark Whittaker

Graham Michael Wynne

Julia Vile

Frank Schroer

Original Assignee

Atopix Therapeutics Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-01-18

Filing date

2009-01-19

Publication date

2014-05-30

2008-01-18 Priority claimed from GB0800874A external-priority patent/GB0800874D0/en

2008-11-10 Priority claimed from GB0820526A external-priority patent/GB0820526D0/en

2009-01-19 Application filed by Atopix Therapeutics Ltd filed Critical Atopix Therapeutics Ltd

2014-05-30 Publication of PL2250161T3 publication Critical patent/PL2250161T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Neurology (AREA)
Diabetes (AREA)
Virology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Oncology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Reproductive Health (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Ophthalmology & Optometry (AREA)

PL09702598T 2008-01-18 2009-01-19 Związki mające aktywność antagonisty CRTH2 PL2250161T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB0800874A GB0800874D0 (en)	2008-01-18	2008-01-18	Compounds having CRTH2 antagonist activity
GB0820526A GB0820526D0 (en)	2008-11-10	2008-11-10	Compounds having crth2 antagonist activity
EP09702598.5A EP2250161B1 (en)	2008-01-18	2009-01-19	Compounds having crth2 antagonist activity
PCT/GB2009/000142 WO2009090414A1 (en)	2008-01-18	2009-01-19	Compounds having crth2 antagonist activity

Publications (1)

Publication Number	Publication Date
PL2250161T3 true PL2250161T3 (pl)	2014-05-30

Family

ID=40473418

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL09702598T PL2250161T3 (pl)	2008-01-18	2009-01-19	Związki mające aktywność antagonisty CRTH2

Country Status (24)

Country	Link
US (1)	US20090186923A1 (pl)
EP (1)	EP2250161B1 (pl)
JP (2)	JP2011509988A (pl)
KR (1)	KR101644170B1 (pl)
CN (1)	CN101932571B (pl)
AU (1)	AU2009204700B2 (pl)
BR (1)	BRPI0906786B1 (pl)
CA (1)	CA2712017C (pl)
CY (1)	CY1114748T1 (pl)
DK (1)	DK2250161T3 (pl)
ES (1)	ES2442717T3 (pl)
HR (1)	HRP20140045T1 (pl)
IL (1)	IL206959A (pl)
MA (1)	MA32075B1 (pl)
MX (1)	MX2010007833A (pl)
MY (1)	MY155133A (pl)
NZ (1)	NZ587251A (pl)
PL (1)	PL2250161T3 (pl)
PT (1)	PT2250161E (pl)
RS (1)	RS53142B (pl)
RU (1)	RU2503672C2 (pl)
SI (1)	SI2250161T1 (pl)
WO (1)	WO2009090414A1 (pl)
ZA (1)	ZA201005799B (pl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6962940B2 (en)	2002-03-20	2005-11-08	Celgene Corporation	(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
GB0324763D0 (en) *	2003-10-23	2003-11-26	Oxagen Ltd	Use of compounds in therapy
WO2009061676A2 (en) *	2007-11-06	2009-05-14	Amira Pharmaceuticals, Inc.	Antagonists of pgd2 receptors
US20100298368A1 (en) *	2007-11-06	2010-11-25	Amira Pharmaceuticals, Inc.	Antagonists of pgd2 receptors
US20110124683A1 (en) *	2007-11-13	2011-05-26	Oxagen Limited	Use of CRTH2 Antagonist Compounds
US7750027B2 (en)	2008-01-18	2010-07-06	Oxagen Limited	Compounds having CRTH2 antagonist activity
NZ587251A (en) *	2008-01-18	2011-12-22	Oxagen Ltd	Indole derivatives having CRTH2 antagonist activity
EP2240444A1 (en) *	2008-01-22	2010-10-20	Oxagen Limited	Compounds having crth2 antagonist activity
WO2009093026A1 (en) *	2008-01-22	2009-07-30	Oxagen Limited	Compounds having crth2 antagonist activity
WO2009099902A1 (en)	2008-02-01	2009-08-13	Amira Pharmaceuticals, Inc.	N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
JP2011512359A (ja) *	2008-02-14	2011-04-21	アミラファーマシューティカルズ，インク．	プロスタグランジンｄ２受容体のアンタゴニストとしての環式ジアリールエーテル化合物
EP2245022A4 (en)	2008-02-25	2012-02-22	Panmira Pharmaceuticals Llc	ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
EP2268611A2 (en) *	2008-04-02	2011-01-05	Amira Pharmaceuticals, Inc.	Aminoalkylphenyl antagonists of prostaglandin d2 receptors
US20110112134A1 (en) *	2008-05-16	2011-05-12	Amira Pharmaceuticals, Inc.	Tricyclic Antagonists of Prostaglandin D2 Receptors
JP2011526281A (ja) *	2008-06-24	2011-10-06	アミラファーマシューティカルズ，インク．	プロスタグランジンｄ２受容体のシクロアルカン［ｂ］インドールアンタゴニスト
US8071807B2 (en) *	2008-07-03	2011-12-06	Panmira Pharmaceuticals, Llc	Antagonists of prostaglandin D2 receptors
GB2463788B (en) *	2008-09-29	2010-12-15	Amira Pharmaceuticals Inc	Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en)	2008-10-01	2010-04-08	Amira Pharmaceuticals, Inc.	Heteroaryl antagonists of prostaglandin d2 receptors
US8524748B2 (en)	2008-10-08	2013-09-03	Panmira Pharmaceuticals, Llc	Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
GB2465062B (en) *	2008-11-06	2011-04-13	Amira Pharmaceuticals Inc	Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
WO2010057118A2 (en)	2008-11-17	2010-05-20	Amira Pharmaceuticals, Inc.	Heterocyclic antagonists of prostaglandin d2 receptors
SG178109A1 (en) *	2009-07-31	2012-03-29	Panmira Pharmaceuticals Llc	Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
SG10201404662YA (en) *	2009-08-05	2014-10-30	Panmira Pharmaceuticals Llc	Dp2 antagonist and uses thereof
MX2012007927A (es)	2010-01-06	2012-08-15	Panmira Pharmaceuticals Llc	Antagonistas de dp2 y usos del mismo.
CN102791689B (zh)	2010-03-22	2014-10-29	埃科特莱茵药品有限公司	3-（杂芳基-氨基）-1,2,3,4-四氢-9h-咔唑衍生物及其作为前列腺素d2受体调节剂的用途
GB201103837D0 (en)	2011-03-07	2011-04-20	Oxagen Ltd	Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
US9096595B2 (en)	2011-04-14	2015-08-04	Actelion Pharmaceuticals Ltd	7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin D2 receptor modulators
JP5893155B2 (ja) *	2011-11-17	2016-03-23	山▲東▼亨利医▲薬▼科技有限▲責▼任公司	Ｃｒｔｈ２受容体拮抗薬としての窒素含有縮合環式化合物
GB201121557D0 (en)	2011-12-15	2012-01-25	Oxagen Ltd	Process
UA112667C2 (uk) *	2011-12-16	2016-10-10	Атопікс Терапеутікс Лімітед	Комбінація антагоніста crth2 і інгібітору протонного насоса для лікування еозинофільного езофагіту
WO2014009302A1 (en) *	2012-07-10	2014-01-16	F. Hoffmann-La Roche Ag	Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection
UY35165A (es)	2012-12-04	2014-06-30	Takeda Pharmaceutical	Método profiláctico o terapéutico para el síndrome de sjogren
KR20150126618A (ko) *	2013-03-14	2015-11-12	셀진 코포레이션	아프레밀라스트를 사용하는 건선성 관절염의 치료
GB201322273D0 (en)	2013-12-17	2014-01-29	Atopix Therapeutics Ltd	Process
AU2014373683B2 (en) *	2013-12-31	2020-05-07	Rapamycin Holdings, Llc	Oral rapamycin nanoparticle preparations and use
MX368179B (es)	2014-03-17	2019-09-23	Idorsia Pharmaceuticals Ltd	Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2.
BR112016021443A8 (pt)	2014-03-18	2017-12-26	Actelion Pharmaceuticals Ltd	Derivados de ácido acético azaindol e seu uso como moduladores de receptor de prostaglandina d2
GB201407820D0 (en) *	2014-05-02	2014-06-18	Atopix Therapeutics Ltd	Polymorphic form
GB201407807D0 (en)	2014-05-02	2014-06-18	Atopix Therapeutics Ltd	Polymorphic form
GB201407813D0 (en) *	2014-05-02	2014-06-18	Atopix Therapeutics Ltd	Polymorphic form
CN106536516B (zh) *	2014-06-09	2019-09-03	住友化学株式会社	用于制备吡啶化合物的方法
EP3188745A1 (en)	2014-08-15	2017-07-12	Celgene Corporation	Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
EA035752B1 (ru)	2015-09-15	2020-08-05	Идорсиа Фармасьютиклз Лтд	КРИСТАЛЛИЧЕСКАЯ ФОРМА (S)-2-(8-((5-ХЛОРПИРИМИДИН-2-ИЛ)(МЕТИЛ)-АМИНО)-2-ФТОР-6,7,8,9-ТЕТРАГИДРО-5Н-ПИРИДО[3,2-b]ИНДОЛ-5-ИЛ)УКСУСНОЙ КИСЛОТЫ И СОДЕРЖАЩИЕ ЕЁ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
JP2020530848A (ja)	2017-08-14	2020-10-29	アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ	３，４−二置換３−シクロブテン−１，２−ジオンおよびその使用
CN113330013B (zh) *	2019-01-10	2022-12-27	石药集团中奇制药技术（石家庄）有限公司	杂环化合物盐及其应用
CN114796264A (zh) *	2021-01-27	2022-07-29	北京北工大科技园有限公司	金络合物在制备治疗新型冠状病毒肺炎的药物中的应用
CN116472034A (zh) *	2020-06-12	2023-07-21	藤济(厦门)生物医药科技有限公司	茚化合物、其药物组合物及其治疗应用
CA3206106A1 (en)	2021-02-10	2022-08-18	Bhaskar Chaudhuri	Methods for ophthalmic delivery of roflumilast
EP4337628A1 (en) *	2021-05-15	2024-03-20	Nucmito Pharmaceuticals Company Limited	Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications
WO2023049809A1 (en)	2021-09-22	2023-03-30	Iolyx Therapeutics, Inc.	Methods of treating ocular inflammatory diseases
CN115192584A (zh) *	2022-06-09	2022-10-18	南方科技大学	一种纳米药物及其制备方法和应用
WO2024104384A1 (en) *	2022-11-16	2024-05-23	Nucmito Pharmaceuticals Co. Ltd.	Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3557142A (en)	1968-02-20	1971-01-19	Sterling Drug Inc	4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
BE790679A (fr)	1971-11-03	1973-04-27	Ici Ltd	Derives de l'indole
GB1407658A (en)	1973-03-06	1975-09-24	Ici Ltd	Process for the manufacture of indole derivatives
GB1460348A (en)	1974-02-04	1977-01-06	Ici Ltd	Quinazoline derivativesa
DK151884C (da)	1979-03-07	1988-06-13	Pfizer	Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
US4363912A (en)	1980-12-15	1982-12-14	Pfizer Inc.	Indole thromboxane synthetase inhibitors
GB8607294D0 (en)	1985-04-17	1986-04-30	Ici America Inc	Heterocyclic amide derivatives
GB9122590D0 (en)	1991-10-24	1991-12-04	Lilly Industries Ltd	Pharmaceutical compounds
US6040426A (en)	1996-06-05	2000-03-21	Bml, Inc.	Human Th2 specific protein
US6916841B2 (en)	1998-02-25	2005-07-12	Genetics Institute, Llc	Inhibitors of phospholipase enzymes
AP2000001929A0 (en)	1998-03-31	2000-09-30	Inst For Pharm Discovery Inc	Substituted indolealkanoic acids.
TNSN99224A1 (fr)	1998-12-01	2005-11-10	Inst For Pharm Discovery Inc	Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
GB9902461D0 (en) *	1999-02-05	1999-03-24	Zeneca Ltd	Chemical compounds
DE60025368T2 (de)	1999-08-23	2006-09-14	Bml Inc.	Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren
EP1166011A1 (en)	2000-01-14	2002-01-02	Koninklijke Philips Electronics N.V.	Display device
AU2001238718A1 (en)	2000-03-02	2001-09-12	The Institutes For Pharmaceutical Discovery, Llc	Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
JP2001247570A (ja)	2000-03-08	2001-09-11	Japan Tobacco Inc	インドール酢酸化合物及びその製造方法
US6878522B2 (en)	2000-07-07	2005-04-12	Baiyong Li	Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
SE0200356D0 (sv)	2002-02-05	2002-02-05	Astrazeneca Ab	Novel use
SE0200411D0 (sv)	2002-02-05	2002-02-05	Astrazeneca Ab	Novel use
WO2003097598A1 (fr)	2002-05-16	2003-11-27	Shionogi & Co., Ltd.	Composé comprenant un antagonisme du récepteur de pdg2
WO2003097042A1 (fr)	2002-05-16	2003-11-27	Shionogi & Co., Ltd.	Antagoniste de recepteur de pdg2
SE0201635D0 (sv)	2002-05-30	2002-05-30	Astrazeneca Ab	Novel compounds
TW200307542A (en)	2002-05-30	2003-12-16	Astrazeneca Ab	Novel compounds
US7364647B2 (en)	2002-07-17	2008-04-29	Eksigent Technologies Llc	Laminated flow device
SE0202241D0 (sv) *	2002-07-17	2002-07-17	Astrazeneca Ab	Novel Compounds
AU2003297398B2 (en)	2002-12-20	2009-09-24	Amgen Inc.	Asthma and allergic inflammation modulators
JP4324418B2 (ja)	2003-08-05	2009-09-02	株式会社日立国際電気	基板処理装置および半導体デバイスの製造方法
SE0302232D0 (sv)	2003-08-18	2003-08-18	Astrazeneca Ab	Novel Compounds
EP1675826A1 (en) *	2003-10-14	2006-07-05	Oxagen Limited	Compounds having crth2 antagonist activity
GB0324763D0 (en) *	2003-10-23	2003-11-26	Oxagen Ltd	Use of compounds in therapy
ATE470443T1 (de)	2004-03-11	2010-06-15	Actelion Pharmaceuticals Ltd	Indol-1-yl-essigsäurederivate
US20090170897A1 (en) *	2004-04-20	2009-07-02	Pfizer, Inc.	Method of Treating Neuropathic Pain
CA2581338A1 (en)	2004-09-21	2006-03-30	Athersys, Inc.	Indole acetic acids exhibiting crth2 receptor antagonism and uses thereof
GB0504150D0 (en)	2005-03-01	2005-04-06	Oxagen Ltd	Microcrystalline material
GB0505048D0 (en) *	2005-03-11	2005-04-20	Oxagen Ltd	Compounds with PGD antagonist activity
PL65781Y1 (pl)	2005-08-16	2012-02-29	Katarzyna Kawczyńska	Wkładka kosmetyczna
US7999119B2 (en) *	2006-07-22	2011-08-16	Oxagen Limited	Compounds having CRTH2 antagonist activity
GB0722203D0 (en) *	2007-11-13	2007-12-19	Oxagen Ltd	Use of CRTH2 antagonist compounds
SI2327693T1 (sl) *	2007-12-14	2012-09-28	Pulmagen Therapeutics Asthma Ltd Fulmer Hal Windmil Road	Indoli in njihova terapevtska raba
NZ587251A (en) *	2008-01-18	2011-12-22	Oxagen Ltd	Indole derivatives having CRTH2 antagonist activity

2009
- 2009-01-19 NZ NZ587251A patent/NZ587251A/en not_active IP Right Cessation
- 2009-01-19 EP EP09702598.5A patent/EP2250161B1/en active Active
- 2009-01-19 CN CN200980103456.8A patent/CN101932571B/zh not_active Expired - Fee Related
- 2009-01-19 PL PL09702598T patent/PL2250161T3/pl unknown
- 2009-01-19 RS RS20140016A patent/RS53142B/en unknown
- 2009-01-19 WO PCT/GB2009/000142 patent/WO2009090414A1/en active Application Filing
- 2009-01-19 HR HRP20140045AT patent/HRP20140045T1/hr unknown
- 2009-01-19 ES ES09702598.5T patent/ES2442717T3/es active Active
- 2009-01-19 MX MX2010007833A patent/MX2010007833A/es active IP Right Grant
- 2009-01-19 SI SI200930822T patent/SI2250161T1/sl unknown
- 2009-01-19 PT PT97025985T patent/PT2250161E/pt unknown
- 2009-01-19 JP JP2010542688A patent/JP2011509988A/ja active Pending
- 2009-01-19 BR BRPI0906786-8A patent/BRPI0906786B1/pt not_active IP Right Cessation
- 2009-01-19 AU AU2009204700A patent/AU2009204700B2/en not_active Ceased
- 2009-01-19 RU RU2010129027/04A patent/RU2503672C2/ru active
- 2009-01-19 CA CA2712017A patent/CA2712017C/en active Active
- 2009-01-19 MY MYPI2010003390A patent/MY155133A/en unknown
- 2009-01-19 KR KR1020107017661A patent/KR101644170B1/ko not_active Expired - Fee Related
- 2009-01-19 DK DK09702598.5T patent/DK2250161T3/da active
- 2009-01-21 US US12/356,822 patent/US20090186923A1/en not_active Abandoned
2010
- 2010-07-12 IL IL206959A patent/IL206959A/en active IP Right Grant
- 2010-08-13 ZA ZA2010/05799A patent/ZA201005799B/en unknown
- 2010-08-13 MA MA33081A patent/MA32075B1/fr unknown
2014
- 2014-01-15 CY CY20141100031T patent/CY1114748T1/el unknown
- 2014-05-07 JP JP2014095946A patent/JP5855162B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP2250161B1 (en)	2013-10-16
AU2009204700B2 (en)	2013-07-04
DK2250161T3 (da)	2014-01-27
CA2712017A1 (en)	2009-07-23
JP5855162B2 (ja)	2016-02-09
BRPI0906786A2 (pt)	2015-07-14
ZA201005799B (en)	2012-01-25
RU2503672C2 (ru)	2014-01-10
AU2009204700A1 (en)	2009-07-23
CN101932571A (zh)	2010-12-29
KR101644170B1 (ko)	2016-08-01
KR20100110361A (ko)	2010-10-12
CA2712017C (en)	2016-08-09
IL206959A0 (en)	2010-12-30
EP2250161A1 (en)	2010-11-17
MX2010007833A (es)	2010-08-11
BRPI0906786B1 (pt)	2021-10-05
HK1145175A1 (en)	2011-04-08
US20090186923A1 (en)	2009-07-23
CN101932571B (zh)	2014-04-23
RU2010129027A (ru)	2012-02-27
PT2250161E (pt)	2014-01-21
JP2014159465A (ja)	2014-09-04
CY1114748T1 (el)	2016-12-14
WO2009090414A1 (en)	2009-07-23
ES2442717T3 (es)	2014-02-13
IL206959A (en)	2014-09-30
NZ587251A (en)	2011-12-22
RS53142B (en)	2014-06-30
HRP20140045T1 (hr)	2014-02-14
MA32075B1 (fr)	2011-02-01
MY155133A (en)	2015-09-15
SI2250161T1 (sl)	2014-04-30
JP2011509988A (ja)	2011-03-31

Publication	Publication Date	Title
IL206959A0 (en)	2010-12-30	Compounds having crth2 antagonist activity
IL196640A0 (en)	2009-11-18	Compounds having crth2 antagonist activity
ZA200807913B (en)	2009-11-25	Salts with CRTH2 antagonist activity
GB0722216D0 (en)	2007-12-27	Use of crth2 antagonist compounds
GB0722203D0 (en)	2007-12-19	Use of CRTH2 antagonist compounds
GB0810902D0 (en)	2008-07-23	New compounds
GB0800035D0 (en)	2008-02-13	Compounds
EP2518041A4 (en)	2013-12-11	benzyl
IL210344A0 (en)	2011-03-31	New compounds
ZA201104777B (en)	2012-03-28	Substituted quinazoline compounds
ZA200900393B (en)	2010-03-31	Compounds having CRTH2 antagonist activity
GB0800367D0 (en)	2008-02-20	Compounds
GB0801674D0 (en)	2008-03-05	Compounds having CRTH2 antagonist activity
ZA201101390B (en)	2011-10-26	Self cleaning arrangement
HU0800478D0 (en)	2008-09-29	New compounds
GB0818365D0 (en)	2008-11-12	Quinoline compounds
GB0801220D0 (en)	2008-02-27	Compounds
GB0801671D0 (en)	2008-03-05	Compounds having crth2 antagonist activity
GB0801131D0 (en)	2008-02-27	Compounds having CRTH2 antagonist activity
GB0820526D0 (en)	2008-12-17	Compounds having crth2 antagonist activity
GB0800874D0 (en)	2008-02-27	Compounds having CRTH2 antagonist activity
GB0801672D0 (en)	2008-03-05	Compounds having crth2 antagonist activity
GB0801132D0 (en)	2008-02-27	Compounds having CRTH2 antagonist activity
EP2463292A4 (en)	2012-12-19	COMPOUND HAVING NEURITY EXCROTING ACTIVITY
EP2276769A4 (en)	2011-08-17	NEW PEPTIDOMIMETIC COMPOUNDS